Asia Oncology Drug Market Outlook to 2019 - Driven by Rising Demand and Intensifying Joint Ventures between Companies
June 2015
225
About the Report
About the Report
The report titled “Asia Oncology Drug Market Outlook to 2019 – Driven by Rising Demand and Intensifying Joint Ventures between Companies” provides a comprehensive analysis of the oncology drug market in Asia. The report covers various aspects such as market size of oncology drugs, segmentation on the basis of therapeutic class, types of cancer, and volume of exports and imports for oncology drugs. The report is useful for pharmaceuticals companies, retail chains, consultants, healthcare professionals and new players venturing in the market. The market is dominated by few global players including Roche, Novartis, Pfizer and others.
Asia Pacific
The Oncology drug market in the Asia, which is hugely driven by rising demand and investment level of government, registered revenues of USD ~ million in 2013. With the advent of new oncology drug manufacturers in the industry, the revenues increased by 7.6% compared to 2013 where the total revenues was USD ~ million. Each segment in the anti-cancer drug market is subject to a gamut of different factors such as prevalence rate of specific type of cancer, price cuts and number of players in the market plays an important role in determining their respective revenues. The oncology drug market of Asia has grown at a CAGR of 4.3% from USD ~ million in’2009 to INR ~ million in 2014. In more developed markets of the Asia-Pacific region, including countries such as Japan and China, the offerings from the market players are expected to be diverse, focused mainly on customized demands. Additionally, the market is predicted to witness expansion in terms of the newer forms of drugs because of rising cancer incidence and growing awareness. The Asia-Pacific oncology drug market is expected to grow at a CAGR of 9.0% from 2015-2019 on account of increasing affluence of consumers towards healthy lifestyles and treatment of cancer in the recent years.
The Asia oncology drug market is dominated by global pharmaceuticals companies that specialize in marketing patented drugs. The market revenues of Roche from sale of anti-cancer drugs have increased noticeably from USD ~ million in 2012 to USD ~ million in 2014, making it the largest player in oncology drug space. Pfizer was the second largest player in 2014. An inclination in the death rates of cancer patients due lack of proper treatment provides a huge opportunity to pharmaceutical companies to deliver effective drugs in the market and thus contributing to higher revenue of anti-cancer drug market.
India
The Oncology drug market in India, which is driven by the development of new alternative therapies, evolving move from chemotherapy to specific cancer targeted therapy, hormone therapy has registered revenues of INR ~ million in 2013. With an entry of new oncology drug manufacturers in the industry, the revenues increased by 65.5% compared to 2013 where the total revenues was INR ~ million. A major factor that has contributed to such a stupendous growth of this market is advances in technologies. Owing to the advancement in technology, the cancer is diagnosed much frequently and thus better treatment can be provided to the patients. The oncology drug market of India has grown at a CAGR of 22.0% from over INR 12 billion in 2009 to INR ~ million in 2014. The main competitors’ in India oncology space includes Cipla Ltd, Sun Pharma Ltd, Dr Reddy Laboratories amongst others. The India oncology drug market is expected to grow at a CAGR of 17.6% from 2015-2019 due to greater influx of patients in cancer care centers due to rising awareness among the people about the right place for best treatment will continue to escalate the growth of oncology treatment in India.
China
Additionally, China has witnessed continuous and substantial rise in the incidence as well as death caused by cancer. This rapid rise has be attributed to factors such as changing lifestyles and dietary patterns, increasing consumption of tobacco, heavy smoking and several other proximate causes. The revenue of oncology market in China increased by 15.0% compared to 2013. The market has grown at a CAGR of 17.3% from USD ~ million in 2009 to USD ~ million in 2014. The market for oncology drugs in China is dominated by local players such as Jiang Su Heng Rui Medicine Co. Ltd, Qilu Pharmaceuticals Co. Ltd and others. The China oncology drug has been anticipated to incline to about USD 30 billion in 2019 from USD ~ billion in 2014. In addition, the share of generic drugs in China Oncology market is expected to rise by a small percentage to around 72% in the year 2019.
The market for oncology drugs in Asia is changing at a rapid rate. Furthermore, new upcoming drugs, investment by government on Healthcare as well as competitive pressures have been significantly changing the market. Revenues from the anti-cancer drug market in the Asia are expected to expand to USD ~ million in 2019 growing with a CAGR of ~% from 2014-2019.
Key Topics Covered in the Report:
- The market size of the oncology drug market in Asia
- The market size of the generic and patented drugs in Asia oncology drug market.
- The market size of the local and global players market Asia oncology drug market.
- The market size of the India oncology and China oncology drug market.
- Market segmentation of the oncology market on the basis of type of cancer, by generic and patented drugs.
- SWOT and Porter Five force Analysis of India and China Oncology Drug market.
- Trends and Development in the Asia oncology drug market.
- Government Regulations in the India and China oncology drug market.
- Competitive landscape detailed company profiles and market share of the major manufacturers of oncology drugs in Asia as well as India, China and others
- Macro Economic factors affecting India and China Oncology drug market.
- Future outlook and projections of Asia Oncology drug market on the basis of – geography.
Products
Products
Generic Cancer Drugs, Patented Cancer Drugs, Chemotherapy, Targeted Therapy, Hormone Therapy, Immuno Therapy, Avsatin, Herceptin, Xalkori, Sutent, Gle
Companies
The Asia oncology drug market revenues have grown at a CAGR of 4.3% from 2009-2014. Boom in ageing population in China and Japan, rising intake of health insurance and an increase in the out of pocket healthcare expenditure will result in increased revenu
Table of Contents
Table of Contents
1. Global Oncology Drug Market Introduction and Size, 2009-2014
2. Asia-Pacific Oncology Drug Market
2.1. Asia-Pacific Oncology Drug Market Introduction and Size, 2009-2014
2.2. Asia-Pacific Oncology Drug Market Segmentation, 2014
2.2.1. By Share of Therapeutic Modalities, 2014
2.2.2. By Generic and Patented Drugs, 2014
2.3. Asia-Pacific Oncology Drug Market Growth Drivers and Restraints
2.3.1. Growth Drivers
Rising Incidence And Prevalence Of Various Cancer Types
Growing Importance Of Biological And Targeted Drug Therapies
Expiration of Key Patents
Health-Insurance
2.3.2. Growth Restraints
Expensive Treatment
Competition from Biosimilars
Competition
2.4. Asia-Pacific Oncology Drug Market SWOT Analysis
2.5. Asia-Pacific Oncology Drug Market Trends and Developments
Shift Towards Personalized Medication
Antibody Drug Conjugates (ADC)
Increasing Usage of Combination Therapy
2.6. Asia-Pacific Oncology Drug Market Competitive Landscape
2.6.1. Market Share of Major Pharmaceutical Companies by Revenue, 2014
2.6.2. Drugs in Pipeline in the next 3 years and 5 years
3. India Oncology Drug Market
3.1. India Oncology Market Introduction
3.2. India Oncology Drug Market-Value Chain Analysis
Raw Material Manufacturer
Pharmaceutical Company
Drug Distribution
Medical Service Provider
Health Buyer
3.3. India Oncology Drug Market Size by Revenues, 2009-2014
3.4. India Oncology Drug Market Segmentation
3.4.1. By Share of Therapeutic Modalities, FY’2014
Chemotherapy
Targeted Therapy
Immunotherapy (Biologics Therapy)
Hormone Therapy
3.5. India Cancer Cases Market Segmentation
3.5.1. By Incidence and Mortality, 2009-2014
3.5.2. By Type of Cancer, 2013-2014
3.6. India Oncology Drug Market Growth Drivers and Restraints
3.6.1. Growth Drivers
Rise in Cancer Incidence rates
Health Care Expenditure
Technological Advancement
Rising Penetration of Health Insurance
Influence Through Hospital Channel
Rising Affordability
3.6.2. Growth Restraints
Rising Input Costs of Drugs
High Treatment Cost
High Level of Competition
Rising Demand for Generic Drugs
Lack of Eminent Oncology Specialists
3.7. India Oncology Drug Market SWOT Analysis
3.8. Porter Five Forces Analysis of India Oncology Drug Market
3.9. Trends and Developments in India Oncology Drug Market
Introduction of Improved Drugs and Therapies
Increased Consolidation
Rising Markets for Bio-Similar
Rising Combination Therapies
3.10. Government Regulations And Initiatives in India Oncology Drug Market
3.10.1. Regulatory Bodies
3.10.2. Licensing and Registration of Pharmaceuticals
3.10.3. Drugs and Cosmetics Act, 1940
3.11. India Oncology Drug Market External Scenario
3.11.1. Paclitaxel and Docetaxel
Imports Demand and Value, FY’2009-FY’2014
Export Sales and Revenue, FY’2009-FY’2014
3.11.2. Etoposide
Export Sales and Revenue, FY’2009-FY’2014
3.11.3. Other Anti-Cancer Drugs
Import Demand and Value, FY’2009-FY’2014
Export Sale and Revenue, FY’2009-FY’2014
3.12. Competitive Landscape of Major Players in India Oncology Drug Market
3.13. Company Profiles of Major Players in Oncology Drug Market
3.13.1. Cipla Ltd.
3.13.1.1. Business Overview
3.13.1.2. Business Strategies
3.13.1.3. Financial and Operational Performance, FY’2009-FY’2014
3.13.1.4. Anti-Cancer Product Portfolio
3.13.2. Sun Pharma-Ranbaxy Laboratories Ltd.
3.13.2.1. Business Overview
3.13.2.2. Business Strategies
3.13.2.3. Financial and Operational Performance, 2009-2014
3.13.2.4. Anti-Cancer Product Portfolio
3.13.3. Dr. Reddy Laboratories Limited
3.13.3.1. Business Overview
3.13.3.2. Business Strategies
3.13.3.3. Financial and Operational Performance, FY’2009-FY’2014
3.13.3.4. Anti-Cancer Product Portfolio
3.13.4. NATCO Pharma Ltd.
3.13.4.1. Business Overview
3.13.4.2. Business Strategies
3.13.4.3. Financial and Operating Performance, FY’2009-FY’2014
Anti- Cancer Product Portfolio
3.13.5. Biocon Limited
3.13.5.1. Business Overview
3.13.5.2. Business Strategies
3.13.5.3. Financial and Operating Performance, FY’2009-FY’2014
3.13.5.4. Anti-Cancer Product Portfolio
3.14. India Oncology Drug Market Future Outlook & Projections, FY’ 2015-FY’2019
3.14.1. Cause and Effect Relationship between Independent and Dependent Factors
3.15. India Oncology Drug Market Future projections, FY’2015-FY’2019
3.16. India Oncology Hospital Market
Evolvement of Oncology Hospitals in the Country
List of Major Oncology Specialty Hospitals in India- State Presence and Number of Beds
3.16.1. India Major Oncology Hospitals Market Size, FY’2010-FY’2014
3.16.2. India Major Oncology Hospitals Market Segmentation, FY’2014
By States, FY’2014
By Type of Cancers, FY’2014
3.16.3. Cost of Key Oncology Procedures in India
Average Cost Procedure for Lung Cancer in India
Average Cost Procedure for Breast Cancer in India
3.16.4. Revenue of Major Oncology Hospitals in India, FY’2014
3.16.5. Future Opportunities to Set up Cancer Specialty Centres in Different States Across India
3.17. Macro Economic Factors Affecting India Oncology Drug Market
3.17.1. Population in India, 2009-2019
3.17.2. Personal Disposable Income in India, FY’2009-FY’2019
3.17.3. Total Spending on Healthcare, FY’2009- FY’2019
3.17.4. Number of Hospitals in India, FY’2009-FY’2019
4. China Oncology Drug Market
4.1. China Oncology Drug Market Introduction
4.2. China Oncology Market-Value Chain Analysis
Research and Development
Active Pharmaceutical Ingredients (APIs) Manufacturing
Formulation Manufacturing
Marketing and Distribution
4.3. China Oncology Drug Market Size, 2009-2014
4.4. China Oncology Drug Market Segmentation
4.4.1. By Generic and Patented Drugs, 2014
4.4.2. By Local Players and Multinational Companies, 2014
4.5. China Cancer Cases Market Segmentation
4.5.1. By Incidence and Mortality, 2010-2012
4.5.2. By New Cases Registered, 2009-2011
4.6. Growth Drivers and Restraints for China Oncology Drug Market
4.6.1. Growth Drivers
Rising Spending on HealthCare
Rise in Cancer Incidence Rates
Increasing Expenditure And Knowhow On Advanced Technologies And Equipments
4.6.2. Growth Restraints
Lack of Awareness Among People
Issue Of Delivering Healthcare Services In Non-Urban Areas
Rise in Penetration For Generic Drugs
Rising Cost of Drugs
4.7. SWOT Analysis of China Oncology Drug Market
4.8. Trends and Developments in China Oncology Drug Market
Enhanced Consolidation
Extension in Demand for Oncology Drugs
Move Towards Targeted Therapies
Ensuring Value for Money
Biosimilar Monoclonal Antibodies
4.9. Government Regulations in China Oncology Drug Market
Government Drug Pricing Policy
Intellectual Property Issues
Drug registration, Approval and Manufacturing
Advertising
Pricing
Reimbursement Mechanism
4.10. China Oncology Drug Market Competitive Landscape
4.10.1. Product Portfolio
Jiang Su Heng Rui Medicine Limited
Qilu Pharmaceuticals Co. Ltd
Jiangsu Hansoh Pharmaceutical
Luye Pharma Group
4.11. China Oncology Drug Market Future Outlook and Projections, 2015-2019
Cause and Effect Relationship between Independent and Dependent Factors
4.12. Macro Economic Factors Affecting China Oncology Drug Market
4.12.1. Population in China, 2009-2019
4.12.2. Personal Disposable Income, 2009-2019
4.12.3. Total Spending on Healthcare, 2009-2019
4.12.4. Number of Hospitals, 2009-2019
5. Snapshot on Japan Oncology Drug Market
5.1. SWOT Analysis for Japan Oncology Drug Market
6. Company Profiles for Asia Pacific Oncology Drug Manufacturers
6.1. Roche
6.1.1. Business Overview
6.1.2. Business Strategies
6.1.3. Financial and Operational Performance, 2009-2014
6.1.4. Product Profile
6.2. Pfizer
6.2.1. Business Overview
6.2.2. Business Strategies
6.2.3. Financial Performance, 2009-2014
6.2.4. Product Profile
6.3. Novartis
6.3.1. Business Overview
6.3.2. Business Strategies
6.3.3. Financial and Operational Performance, 2009-2014
6.3.4. Product Profile
6.4. AstraZeneca
6.4.1. Business Overview
6.4.2. Business Strategies
6.4.3. Financial Performance, 2009-2014
6.4.4. Product Profile
6.5. Celegne
6.5.1. Business Overview
6.5.2. Business Strategies
Organizational Structure
6.5.3. Financial Performance, 2009-2014
6.5.4. Product Profile
6.6. Eli-Lilly
6.6.1. Business Overview
6.6.2. Business Strategies
6.6.3. Financial Performance, 2009-2014
6.6.4. Product Profile
6.7. GlaxoSmithKline
6.7.1. Business Overview
6.7.2. Business Strategies
6.7.3. Financial Performance, 2009-2014
6.7.4. Product Profile
7. Asia-Pacific Oncology Drug Market Future Outlook and Projections, 2015-2019
7.1. By Geography
8. Appendix
8.1. Market Definition
8.2. Abbreviations
8.3. Research Methodology
Data Collection Methods
Approach
Variables (Independent and Dependent)
Final Conclusion
8.4. Disclaimer
List of Figure
Figure 1: Global Oncology Drug Market Size on the Basis of Revenue in USD Million and Growth Rate in Percentage, 2009-2014
Figure 2: Global Oncology Market Segmentation by Therapeutic Modalities in Percentage, 2009-2013
Figure 3: Market Share of Major Pharmaceutical Players in Global Oncology Drug Market on the Basis of Revenue in Percentage, 2014
Figure 4: Asia-Pacific Oncology Drugs Market Size on the Basis of Industry Revenue in USD Million, 2009-2014
Figure 5: India Oncology Drug Market Value Chain Analysis
Figure 6: India Oncology Drug Market Size on the Basis of Revenue in INR Million, 2009-2014
Figure 7: India Oncology Drug Market Segmentation by Share of Therapeutic Modalities in Percentage, 2014
Figure 8: Porter Five Forces Analysis of India Oncology Drug Market
Figure 9: India Paclitaxel and Docetaxel Import Value in INR Million, FY’2009FY’2014
Figure 10: India Paclitaxel and Docetaxel Imports by Major Destinations on the Basis of Revenue in Percentage, FY’2014
Figure 11: India Paclitaxel and Docetaxel Exports Value in INR Million, FY’2009-FY’2014
Figure 12: India Export of Paclitaxel and Docetaxel Drug to Top 5 Exporting Nations in Percentage, FY’2014
Figure 13: India Etoposide Exports Value in INR Million, FY’2009-FY’2014
Figure 14: India Other Anti-Cancer Drugs Imports Value in INR Million, FY’2009-FY’2014
Figure 15: India Imports of Other Anti- Cancer Drugs from Major Importing Nations in Percentage, FY’2014
Figure 16: India Other Anti-Cancer Drugs Exports Value in INR Million, FY’2009-FY’2014
Figure 17: India Export of Other Anti- Cancer Drugs to Major Exporting Nations in Percentage, FY’2014
Figure 18: Key Milestones achieved by CIPLA Limited
Figure 19: CIPLA Ltd Revenue in INR Million and Growth Rate in Percentage from India, FY’2009-FY’2014
Figure 20: Revenue Segmentation of Cipla Ltd on the Basis of Exports and Domestic Revenue in USD Million, FY’2009-FY’2014
Figure 21: Ranbaxy Laboratories Ltd: Key Milestones
Figure 22: Sun Pharma Ltd Revenue in Formulation Segment from India in INR Million, 2009-2014
Figure 23: Sun Pharma Ltd Revenue Segmentation across Business Segments in Percentage Terms, FY’2010-FY’2014
Figure 24: Dr Reddy Laboratories Ltd Total Revenue from India in INR Million, FY’2010-FY’2014
Figure 25: Dr Reddy Laboratories Ltd India’s Revenue Segmentation on the Basis of Generics and PSAI in INR Million, FY’2010-FY’2014
Figure 26: NATCO Pharma Limited: Key Milestones
Figure 27: Natco Pharma Ltd Revenue from Oncology Segment in India in INR Million, FY’2009-FY’2014
Figure 28: NATCO Pharma Ltd Revenue Segmentation in Percentage, FY’2014
Figure 29: Biocon Limited Changing Organization Structure from Function Based to Strategic Business Units
Figure 30: Biocon Limited Revenue from Sales in India in INR Million and Growth Rate in Percentage (%), FY’2009-FY’2014
Figure 31: Biocon Limited Revenue Segmentation in Percentage, 2010-2014
Figure 32: India Oncology Drug Market Future Projections by Revenue in INR Million, FY’2015-FY’2019
Figure 33: India Oncology Single Specialty Hospitals Market Size by Revenue in INR Million, FY’2010-FY’2014
Figure 34: India Oncology Single Specialty Hospitals Market Segmentation by States in Percentage (%), FY’2014
Figure 35: India Oncology Single Specialty Hospitals Market Segmentation by Types of Cancers on the Basis of Revenue Contribution in Percentage (%), FY’2014
Figure 36: Total Population in India in Million, 2009-2019
Figure 37: Middle Class Population of India in Million, 2009 - 2019
Figure 38: Upper Class Population of India in Million, 2009 -2019
Figure 39: India Population Demography by Age Structure, 2014
Figure 40: Personal Disposable Income in India in INR Billion, FY’2010- FY’2019
Figure 41: Total HealthCare Expenditure in India in INR Billion, 2009-2019
Figure 42: Total Spending on Healthcare Segmentation in Percentage (%), FY’2009-FY’2019
Figure 43: Total Number of Hospitals in India, FY’2009-FY’2019
Figure 44: Number of Government Hospitals in India, FY’2009-FY’2019
Figure 45: Number of Oncology Drugs in Pipeline in China
Figure 46: China Oncology Drug Market- Value Chain Analysis
Figure 47: China Oncology Drugs Market Size on the Basis of Revenue in USD Million, 2009-2014
Figure 48: Number of New Case Registered Segmentation by Gender in Absolute Numbers, 2008-2011
Figure 49: New Cases Registered Segmentation by Gender in Percentage (%), 2008-2011
Figure 50: China's Approval Procedures for New Drugs
Figure 51: Share of Top 10 Players in China’s Oncology Market, 2013
Figure 52: Share of Major Global Players in China’s Oncology Market, 2013
Figure 53: China Anti-cancer Drug Market Future Projections on the Basis of Sales Revenues in USD Million, 2015-2019
Figure 54: China Anti-cancer Drug Industry Segmentation by Generic and Patented Drugs on the Basis of Revenue in Percentage, 2019
Figure 55: Total Population of China in Million, 2009-2019
Figure 56: Personal Disposable Income of China in USD Thousand, 2009-2019
Figure 57: Per Capita Disposable Income of China in USD, 2009-2019
Figure 58: Total Spending on Health Care in China in USD Billion, 2009-2019
Figure 59: Number of Hospitals in China, 2009-2019
Figure 60: Japan Oncology Market Size in USD Million and Growth Rate in Percentage, 2009-2014
Figure 61: Segmentation of Deaths Due to Cancer by Gender in Japan, 2009-2012
Figure 62: Global Sale of Anti-Cancer Drugs by Roche in USD Million, 2009-2014
Figure 63: Global Sale of Anti-Cancer Drugs by Pfizer in USD Million, 2009-2014
Figure 64: Revenue Segmentation of Pfizer from Different Segments in Percentage, 2012-2014
Figure 65: Global Sale of Anti-Cancer Drugs by Novartis in USD Million, 2009-2014
Figure 66: Global Sales of Anti-Cancer Drugs by AstraZeneca in USD Million, 2009-2014
Figure 67: Global Sales of Anti-Cancer Drugs by AstraZeneca in USD Million, 2009-2014
Figure 68: Global Sales of Oncology Products by Eli-Lilly in USD Million, 2009-2014
Figure 69: Eli-Lilly Revenue Segmentation by Geography in Percentage, 2014
Figure 70: Global Sales of Oncology Product by GSK in USD Million, 2009-2014
Figure 71: Segmentation of Total Revenue by Geography in Percentage, 2009-2014
Figure 72: Asia-Pacific Oncology Drug Market Future Projections on the Basis of Revenues in INR Million, 2015-2019
List of Table
Table 1: Asia-Pacific Oncology Drug Market Segmentation by Share of Therapeutic Modalities in Percentage and USD Million, 2014
Table 2: Asia-Pacific Anti Cancer Drug Market Segmentation by Generic and Patented Drugs on the Basis of Sales in USD Million and Contribution in Percentage, 2014
Table 3: SWOT Analysis of Asia-Pacific Oncology Market
Table 4: Personalized Medicine Drugs for Breast Cancer by Biomaker, Compound and Indication
Table 5: Antibody Drug Conjugates Currently in Clinical Development Stage and their Target Antigen
Table 6: Market Share of Major Pharmaceutical Companies on the basis of Major Drugs, Number of Patents and Sales of Major Drugs in USD Million, 2014
Table 7: Comparative Analysis of Major Cancer Drugs Brands in Pipeline and Development Phase Stage
Table 8: India Oncology Drug Market Segmentation by Share of Therapeutic Modalities in INR Million, 2014
Table 9: Number of New Cancer Cases Registered in India in Million, 2009-2014
Table 10: Cancer Incidence in India by States, 2011-2013
Table 11: Cancer Mortality in India by States, 2011-2013
Table 12: India Cancer Market Segmentation by Types of Cancer, 2013-2014
Table 13: India Oncology Drug Market SWOT Analysis
Table 14: Rising Share of Targeted Oncology Therapies, 2010
Table 15: India Paclitaxel and Docetaxel Imports by Major Destinations on the Basis of Value in INR Million and Volume in Thousand Kilograms, FY’2014
Table 16: India Paclitaxel and Docetaxel Exports by Major Destinations on the Basis of Value in INR Million and Volume in Thousand Kilograms, FY’2014
Table 17: India Etoposide Exports Segmentation by Major Destinations on the Basis of Value in INR Million and Volume in Thousand Kilograms, FY’2014
Table 18: India Other Anti-Cancer Drugs Imports Segmentation by Major Destinations on the Basis of Value in INR Million and Volume in Thousand Kilograms, FY’2014
Table 19: India Other Anti-Cancer Drugs Exports Segmentation by Major Destinations on the Basis of Value in INR Million and Volume in Thousand Kilograms, FY’2014
Table 20: Competitive Landscape of Major Domestic Players in India Oncology Drug Market
Table 21: Global Research and Development Expenses of Cipla Ltd in INR Million, FY’2009-FY’2014
Table 22: Anti-cancer Drug Portfolio of CIPLA Ltd
Table 23: Sun Pharma Ltd- Key Deals and Rationale
Table 24: Sun Pharma Ltd Financial and Operating Performance on the Basis of Revenues in INR Million, FY’2009-FY’2014
Table 25: Sun Pharma Ltd/Ranbaxy Laboratories Anti-Cancer Product Profile
Table 26: Number of New Low-Competition Product Launched by Dr Reddy Laboratories, FY’2011-FY’2014
Table 27: Dr. Reddy Laboratories Oncology Drugs In Pipeline
Table 28: Dr Reddy Laboratories Limited Global Research and Development Expenses in INR Million, FY’2009-FY’2014
Table 29: Anti-cancer Drug Portfolio of Dr Reddy’s Laboratories Limited
Table 30: Natco Pharma Limited Financial and Operating Performance in INR Million, FY’2009-FY’2014
Table 31: Anti-Cancer Drug Profile of NATCO Pharmaceuticals Ltd
Table 32: Biocon’s Key Milestones 2010-2014
Table 33: SWOT Analysis of Biocon Limited
Table 34: Biocon Limited Revenue Segmentation in INR Million, FY’2010-FY’2014
Table 35: Anti-cancer Product Portfolio of Biocon Limited
Table 36: Cause and Effect Relationship between the Macro-Economic and Industry Factors and India Oncology Drug Market Future Prospects
Table 37: List of Major Oncology Hospitals in India by State Presence and Number of Beds
Table 38: List of Regional Cancer Care (RCC) Centres in India by State and City Presence
Table 39: Number of Oncologists and Oncologist to Cancer Patient Ratio in India and the US
Table 40: Renowned Single Specialty and Multispecialty Cancer Care Hospital by Region
Table 41: Average Cost of Treatment of Lung Cancer by Diagnosis, Chemotherapy and Radiation Sittings and Medicinal Costs in INR
Table 42: Average Cost of Treatment of Breast Cancer by Chemotherapy and Radiation Sittings and Medicinal Costs in INR
Table 43: Revenue of Major Oncology Single Specialty Hospitals in India in INR Million, FY’2014
Table 44: Analysis of Future Opportunities to Set up Oncology Single Specialty Hospitals in India by Different States
Table 45: Estimated Cost of Treatment per Cycle in China and Other Countries in USD
Table 46: Market Share by Line of Therapy for Branded Oncology Products in China
Table 47: China Anti Cancer Drug Market Segmentation by Generic and Patented Drugs on the Basis of Sales in USD Million and Contribution in Percentage, 2014
Table 48: China Anti Cancer Drug Market Segmentation by Local and Global Players in Market on the Basis of Sales in USD Million and Contribution in Percentage, 2014
Table 49: Incidence of Cancer in China, 2010-2012
Table 50: Deaths due to Cancer in China, 2010-2012
Table 51: Number of New Cancer Cases in China, 2008-2011
Table 52: China Anti-cancer Drug Market SWOT Analysis
Table 53: Competitive Landscape of Major Local Pharmaceutical Companies in China Oncology Drug Market
Table 54: Anti-Cancer Product Profile of Jiang Su Heng Rui Medicine Co. Ltd
Table 55: Anti-Cancer Product Profile of Qilu Pharmaceuticals Co. Ltd
Table 56: Anti- Cancer Product Portfolio of Jiangsu Hansoh Pharmaceutical
Table 57: Anti-Cancer Product Profile of Luye Pharma Group
Table 58: Cause and Effect Relationship between the Macro-Economic and Industry Factors and China Oncology Drug Market Future Prospects
Table 59: Number of New Cases and Deaths Due to Different Cancers in Japan, 2012
Table 60: Snapshot of Population and Number of Doctors in Japan, 2012
Table 61: Treaters of Cancer in Japan, 2012
Table 62: SWOT Analysis of Japan Anti-Cancer Drug Market
Table 63: Types of Anti Cancer Therapy Provided by Roche
Table 64: Global Research and Development Expenses of Roche in USD Million, 2009-2013
Table 65: Roche Anti-cancer Drug Portfolio
Table 66: Cancer Drug Pipeline of Roche
Table 67: Global Research and Development Expenses of Pfizer in USD Million, 2009-2014
Table 68: Anti-cancer Drug Portfolio of Pfizer
Table 69: Pfizer Anti-Cancer Drug Pipeline
Table 70: Major Development Projects of Novartis in Oncology Segment
Table 71: Global Research and Development Expenses of Novartis in USD Million, 2009-2013
Table 72: Anti-cancer Drug Portfolio of Novartis
Table 73: Anti-Cancer Drug Portfolio of AstraZeneca
Table 74: Anti-cancer Drugs in Pipeline of Astrazeneca
Table 75: Net Sales of Major Oncology Products by Celgene in USD Million, 2009-2014
Table 76: Anti- Cancer Drug Profile of Celgene
Table 77: Anti- Cancer Drug in Pipeline of Celgene
Table 78: Eli-Lily Anti –Cancer Drug Profile
Table 79: Eli-Lilly Anti-Cancer Drugs in Pipeline
Table 80: GSK Anti-Cancer Drug Profile
Table 81: GSK Anti-Cancer Drug in Pipeline
Table 82: Correlation Matrix of the India Oncology Drug Industry
Table 83: Regression Coefficients Output for India Oncology Drug Market
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.